Propranolol

• Description:

  Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  Adrenergic Receptor; Bacterial

• Type:

  Natural Products

• Related Pathways:

  Anti-infection; GPCR/G Protein; Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Neurological Disease; Cardiovascular Disease; Endocrinology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/propranolol.html

• Purity:

  99.91

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  OC(COC1=C2C=CC=CC2=CC=C1)CNC(C)C

• Molecular Formula:

  C16H21NO2

• Molecular Weight:

  259.34

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Galandrin S, et al. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006 Nov;70 (5) :1575-84. Epub 2006 Aug 1|[2]Briley M, et al. Evidence against beta-adrenoceptor blocking activity of diltiazem, a drug with calcium antagonist properties. Br J Pharmacol. 1980 Aug;69 (4) :669-73.|[3]Al-Majed AA, et al. Propranolol. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338.|[4]Munabi NC, et al. Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation. Stem Cells Transl Med. 2016 Jan;5 (1) :45-55.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• Isoform:

  β adrenergic receptor

• Citation 01:

  Acta Pharm Sin B. 2024 Apr 23.|Adv Sci (Weinh) . 2025 Oct 6:e04817.|Aging Cell. 2025 Jul 26:e70184.|Am J Pathol. 2023 Jul;193 (7) :913-926.|Bone Res. 2024 Mar 21;12 (1) :18.|Chem Eng J. 2025 Oct 17;524:169736.|Environ Toxicol. 2024 Mar;39 (3) :1682-1699.|Exp Neurol. 2023 Jul:365:114418.|Food Chem Toxicol. 2024 Sep 6:114983.|iScience. 2023 Jul 22;26 (9) :107455.|J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jul 1:1227:123804.|J Immunother Cancer. 2024 Dec 9;12 (12) :e009910.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|Nat Commun. 2023 May 2;14 (1) :2523.|Pharmaceuticals (Basel) . 2025 Sep 21;18 (9) :1420.|Pharmacol Res Perspect. 2020 Apr;8 (2) :e00575.|Pharmacol Res Perspect. 2021 Oct;9 (5) :e00879.|Phytomedicine. 2024 Aug 19:134:155970.|Phytomedicine. 2025 Jun 18:145:157011.|Redox Biol. 2024 Dec 21:79:103481.|Redox Rep. 2025 Dec;30 (1) :2494314.|Research Square Print. December 21st, 2022.|Sci Signal. 2020 Nov 24;13 (659) :eaax0273.|Transl Psychiatry. 2025 May 17;15 (1) :172.|World J Surg Oncol. 2025 Mar 28;23 (1) :103.|Behav Brain Res. 2022 Feb 10:418:113642.|Biochem Biophys Res Commun. 2023 May 21:657:69-79.|bioRxiv. 2024 November 03.|BMC Pulm Med. 2021 Jun 5;21 (1) :189.|Cell Metab. 2024 Mar 5;36 (3) :466-483.e7.|Cell. 2025 Jan 9;188 (1) :157-174.e22.|Chemosphere. 2019 Jun:225:378-387.|Curr Issues Mol Biol. 2025 Sep 26;47 (10) :798.|Elife. 2024 May 29.|J Endocrinol. 2020 Mar;244 (3) :459-471.|Nature. 2025 Dec;648 (8092) :146-156.|Pharmaceuticals (Basel) . 2025 Sep 21;18 (9) :1420.|Psychopharmacology (Berl) . 2023 Aug;240 (8) :1629-1650.

• CAS Number:

  [525-66-6]